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Background: DNA vaccines have emerged as attractive candidates for the control of human papillomavirus (HPV)-
associated malignancies. However, DNA vaccines suffer from limited immunogenicity and thus strategies to
enhance DNA vaccine potency are needed. We have previously demonstrated that for DNA vaccines encoding
HPV-16 E7 antigen (CRT/E7) linkage with calreticulin (CRT) linked enhances both the E7-specific CD8+ T cell immune
responses and antitumor effects against E7-expressing tumors. In the current study, we aim to introduce an approach
to elicit potent CD4+ T cell help for the enhancement of antigen-specific CD8+ T cell immune responses generated by
CRT/E7 DNA vaccination by using co-administration of a DNA vector expressing papillomavirus major and minor capsid
antigens, L1 and L2.
Result: We showed that co-administration of vectors containing codon-optimized bovine papillomavirus type 1 (BPV-1)
L1 and L2 in combination with DNA vaccines could elicit enhanced antigen-specific CD8+ in both CRT/E7 and ovalbumin
(OVA) antigenic systems. We also demonstrated that co-administration of vectors expressing BPV-1 L1 and/or L2 DNA with
CRT/E7 DNA led to the generation of L1/L2-specific CD4+ T cell immune responses and L1-specific neutralizing antibodies.
Furthermore, we showed that co-administration with DNA encoding BPV1 L1 significantly enhances the therapeutic
antitumor effects generated by CRT/E7 DNA vaccination. In addition, the observed enhancement of CD8+ T cell immune
responses by DNA encoding L1 and L2 was also found to extend to HPV-16 L1/L2 system.
Conclusion: Our strategy elicits both potent neutralizing antibody and therapeutic responses and may potentially be
extended to other antigenic systems beyond papillomavirus for the control of infection and/or cancer.
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The knowledge that high risk human papillomavirus
(HPV) is a necessary etiological factor for the develop-
ment of cervical cancer provides the opportunity for
control of cervical cancer and/or other HPV-associated
malignancies through vaccination against HPV. Cur-
rently, the two commercially available prophylactic vac-
cines, Gardasil and Cervarix, based upon virus-like* Correspondence: chung2@jhmi.edu
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L1 effectively protect against infection by the two most
common HPV types found in cervical cancer (for review
see [1]). The minor capsid antigen L2 also shows prom-
ise for preventive vaccination in animal models,
although it is less immunogenic than L1 VLP. However,
neither L1 VLP nor L2-based vaccines generate thera-
peutic effects against established HPV infection [2].
Therefore, given the significant burden of HPV-
associated lesions worldwide, there is an urgent need to
develop therapeutic HPV vaccines for the control of
existing HPV infection and associated malignancies.cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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the viral capsid proteins L1 and/or L2, therapeutic HPV
vaccines focus on targeting the HPV E6 and E7, since
only these oncoproteins are consistently expressed in
HPV-associated cancers and are responsible for the ma-
lignant transformation.
Among the various therapeutic HPV vaccines cur-
rently being tested, DNA vaccines have emerged as
attractive candidates for the treatment of cervical cancer
and associated malignancies. Naked DNA is relatively
safe, stable, and easy to produce and transport (for re-
view see [3]). Furthermore, DNA vaccines are capable of
sustained cellular gene expression, promote MHC class I
antigen presentation, and have the capacity for repeated
administration since they do not lead to the generation
of neutralizing antibodies. However, an important limita-
tion of DNA vaccines is limited potency since they lack
the intrinsic ability to amplify and spread in vivo. There-
fore, it is important to consider strategies to improve
DNA vaccine potency strategies (for review, see [4, 5]).
One strategy to enhance DNA vaccine potency is to
improve antigen expression, processing, and presenta-
tion in antigen-presenting cells using intracellular target-
ing strategies (for review, see [4, 5]). Several of our
previous studies have employed DNA vaccines encoding
calreticulin (CRT) linked to HPV-16 E7 antigen (CRT/
E7) [6–11] because this fusion greatly enhances the E7-
specific CD8+ T cell immune responses in vaccinated
mice. This phenomenon likely reflects the efficient rec-
ognition of calreticulin by dendritic cells and improved
targeting to the MHCI pathway by targeting to the
endoplasmic reticulum [6].
Activation and proliferation of CD4+ T cells is crucial
to the success of both humoral and cell-mediated re-
sponses to viral infection. Although the fusion of E7
with CRT enables such DNA vaccines to elicit significant
E7-specific CD8 T cell immunity in the absence of CD4
T cell help [12], approaches to boost CD4+ T cell help
are likely to enhance DNA vaccine potency. Indeed, CD4
+ T cells play a significant role in priming effector CD8+
T cells, thus augmenting the CD8+ T cell responses, as
well as generation of memory T cell populations (for re-
view see [13]). CD4+ T cells help to differentiate naïve
CD8+ T cells into effector cells by providing activation
signals to dendritic cells (DCs), most notably IL-2, thus
promoting CD8+ T cell proliferation. Thus, strategies to
induce CD4+ T helper cells at sites of CD8+ T cell prim-
ing can potentially enhance CTL immune responses.
In the current study, we aim to combine intracellular
targeting strategies using CRT with a strategy to en-
hance CD4+ T help for the development of a therapeutic
HPV DNA vaccine. Since papillomavirus L1 or L2 anti-
gens likely contain CD4+ T cell epitopes [14–18], we rea-
soned that co-administration of vectors containingcodon-optimized bovine papillomavirus (BPV) L1 and L2
may provide CD4+ T cell help and enhance the antigen-
specific CD8+ T cell immune responses generated by
DNA vaccines. An additional potential benefit would be
the induction of neutralizing antibody and protective im-
munity [19, 20]. We showed that co-administration of
vectors containing BPV L1 or L2 DNA in combination
with DNA vaccines could elicit enhanced antigen-specific
CD8+ in both CRT/E7 and ovalbumin (OVA) antigenic
systems. We also demonstrated that co-administration of
vectors containing BPV1 L1 ± L2 DNA with CRT/E7
DNA led to the generation of L1/L2-specific CD4+ T cell
immune responses as well as L1-specific neutralizing anti-
bodies. Furthermore, we showed that co-administration
with BPV1 L1 significantly enhances the therapeutic anti-
tumor effects generated by CRT/E7 DNA vaccination. In
addition, the observed enhancement of CD8+ T cell im-
mune responses by DNA encoding L1 and L2 was also
found to extend to HPV-16 L1/L2 system. Overall, our
data suggest that co-administration of DNA encoding
papillomavirus L1 or L2 can be used to enhance antigen-
specific CD8+ T cell immune responses generated by
therapeutic HPV DNA vaccination for the control of HPV
infection and HPV-associated tumors. Furthermore, our
approach can also generate neutralizing antibodies against
papillomavirus for potential prevention against infection.
This strategy also provides the opportunity to combine
preventive and therapeutic approaches. Our strategy may
potentially be extended to other antigenic systems for the
control of infection and/or cancer.
Results
Co-administration with vectors encoding papillomavirus
L1 or L2 significantly enhances the antigen-specific CD8+
T cell immune responses generated by CRT/E7 or OVA
DNA vaccination
In order to characterize the antigen-specific CD8+ T cell
immune responses generated by vaccination with CRT/
E7 or OVA DNA in combination with vectors containing
codon-optimized BPV1 L1 or L2 DNA, C57BL/6 mice
(five per group) were vaccinated intradermally via gene
gun with CRT/E7 or OVA DNA with or without BPV1
L1 or L2 DNA twice at 1-week intervals. Splenocytes
from vaccinated mice were collected 1 week after last
immunization and the E7 or OVA-specific T cell im-
mune responses were characterized using intracellular
cytokine staining followed by flow cytometry analysis. As
shown in Fig. 1, mice vaccinated with CRT/E7 or OVA
DNA vaccine in combination with BPV1-L1 or L2 DNA
generated significantly higher E7-specific and OVA-
specific CD8+ T cell immune responses compared to
mice vaccinated with CRT/E7 or OVA DNA alone. To
evaluate whether the enhancement of antigen-specific
CD8+ T cell immune responses by co-administration of
Fig. 1 Characterization of antigen-specific CD8+ T cell immune responses generated by antigen-specific DNA vaccine mixed with vectors
containing BPV1 L1 or L2 DNA. C57BL/6 mice (five per group) were vaccinated intradermally via gene gun with 2 μg/mouse of CRT/E7 or OVA
DNA with or without BPV1 L1 or L2 DNA twice at 1-week intervals. Splenocytes from vaccinated mice were collected 1 week after last
immunization and the E7 or OVA-specific T cell immune responses were characterized using intracellular cytokine staining followed by flow
cytometry analysis. a Representative flow cytometry data depicting the number of E7 (upper panel) or OVA(lower panel)-specific CD8+ T cells.
b Bar graph representing the number of E7 (upper panel) or OVA (lower panel) -specific CD8+ T cells/3x105 splenocytes (mean ± SD). Data
shown are representative of two experiments performed. * indicates p < 0.05
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mavirus systems, we co-administered HPV16 L1 or L2
DNA with CRT/E7 or OVA DNA vaccination. Of note,
co-administration of HPV16 L1 or L2 DNA with CRT/
E7 or OVA DNA vaccination also generated significantly
higher E7-specific CD8+ T cell responses compared to
CRT/E7 or OVA DNA vaccination alone in mice (Fig. 2).
Thus, our data indicate that co-administration with
papillomavirus L1 or L2 DNA significantly enhances the
antigen-specific CD8+ T cell immune responses gener-
ated by DNA vaccination.
Co-administration of papillomavirus L1 or L2 DNA with
CRT/E7 or OVA DNA led to the generation of L1/L2-
specific CD4+ T cell immune responses
In order to determine whether the co-administration
with BPV1 L1 or L2 DNA with CRT/E7 DNA will lead
to the generation of L1 or L2-specific CD4+ T cell im-
mune responses, C57BL/6 mice (five per group) were
vaccinated intradermally via gene gun with CRT/E7
DNA with BPV1 L1 or L2 DNA. Mice vaccinated with
CRT/E7 DNA alone were used as negative controls.Splenocytes from vaccinated mice were collected 1 week
after last immunization and incubated with BPV1 L1/
L2 virus-like particles (VLPs). The L1 or L2-specific
CD4+ T cell immune responses were characterized
using intracellular cytokine staining followed by flow
cytometry analysis. As shown in Fig. 3a and b, mice
vaccinated with BPV1 L1 in combination with CRT/E7
DNA led to the generation of L1-specific CD4+ T cell
immune responses. Similarly, vaccination with BPV1 L2
with CRT/E7 DNA led to significant level of L2-specific
CD4+ T cell immune responses compared to vaccin-
ation with CRT/E7 alone. Again, to observe whether
the CD4+ T cell responses elicited by this vaccination
strategy extend to other papillomavirus systems, we co-
administered HPV16 L1 or L2 DNA with CRT/E7 or
OVA DNA vaccination. As shown in Fig. 3c and d,
compared to vaccination with CRT/E7 or OVA DNA
alone, mice vaccinated with HPV-16 L1 or L2 DNA in
combination with CRT/E7 or OVA DNA led to the
generation of L1 or L2-specific CD4+ T cell immune re-
sponses. These results suggest that co-administration
with DNA encoding papillomavirus L1 or L2 with
Fig. 2 Characterization of antigen-specific CD8+ T cell immune responses generated by antigen-specific DNA vaccine mixed with HPV-16 L1 or L2
DNA. C57BL/6 mice (five per group) were vaccinated intradermally via gene gun with 2 μg/mouse of CRT/E7 or OVA DNA with or without HPV-
16 L1 or L2 DNA twice at 1-week intervals. Splenocytes from vaccinated mice were collected 1 week after last immunization and the E7 or OVA-
specific T cell immune responses were characterized using intracellular cytokine staining followed by flow cytometry analysis. a Representative
flow cytometry data depicting the number of E7 (upper panel) or OVA (lower panel)-specific CD8+ T cells. b Bar graph representing the number
of E7 (upper panel) or OVA (lower panel)-specific CD8+ T cells/3x105 splenocytes (mean± SD). Data shown are representative of two experiments
performed. * indicates p < 0.05
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L2-specific CD4+ T cell immune responses respectively
in vaccinated mice.
Co-administration with BPV1 L1 DNA significantly
enhances the therapeutic antitumor effects generated by
CRT/E7 DNA vaccination
In order to determine if the observed enhancement of
antigen-specific CD8+ T cell immune responses by co-
administration of BPV1 L1 DNA can translate into po-
tent therapeutic antitumor effects, we performed in vivo
tumor treatment experiments using an HPV-16 E7-
expressing murine tumor cell line, TC-1. TC-1 also ex-
presses HPV16 E6, but does not contain either L1 or L2.
C57BL/6 mice (five per group) were first challenged with
TC-1 tumor cells subcutaneously. One week after tumor
challenge, mice were treated intradermally via gene gun
with CRT/E7 DNA alone, BPV1 L1 DNA alone or CRT/
E7 DNA in combination with BPV1 L1 DNA. Vaccinated
mice were boosted twice at 1-week intervals with the
same dose and regimen. Tumor growth were monitored
twice weekly by caliper measurements and palpations.
As shown in Fig. 4, tumor-bearing mice treated with
CRT/E7 DNA vaccine in combination with BPV1 L1
DNA generated significantly reduced tumor volume andprolonged survival compared to mice treated with CRT/
E7 DNA alone or BPV1 L1 DNA alone. Thus, our data
indicate that co-administration with BPV1 L1 DNA is
capable of significantly enhancing the therapeutic antitu-
mor effects generated by CRT/E7 DNA vaccination.
The enhancement in E7-specific CD8+ T cell immune
responses are contributed by CD4+ T helper cells
In order to determine the mechanism underlying the ob-
served enhancement of antigen-specific CD8+ T cell im-
mune responses generated by coadministration with L1
or L2 DNA vectors, we have generated pcDNA3 encod-
ing the reverse sequences of L1 (BPV L1 (−)) or L2
DNA (BPV L2 (−)). C57BL/6 mice (five per group) were
vaccinated intradermally via gene gun with CRT/E7
DNA with or without the reverse sequence of BPV1 L1
or L2 DNA twice at 1-week intervals. Splenocytes from
vaccinated mice were collected 1 week after last
immunization and the E7-specific T cell immune re-
sponses were characterized using intracellular cytokine
staining followed by flow cytometry analysis. We found
that mice vaccinated with CRT/E7 DNA vaccine in com-
bination with the reverse sequence BPV1-L1 or L2 DNA
did not lead to the increased frequency of E7-specific
CD8+ T cell immune responses observed in mice
Fig. 3 Characterization of BPV1 and HPV-16 L1 or L2-specific CD4+ T cell immune responses generated by CRT/E7 or OVA DNA mixed with
DNA encoding BPV1 or HPV-16 L1 or L2. C57BL/6 mice (five per group) were vaccinated intradermally via gene gun with 2 μg/mouse of CRT/
E7 with or without BPV1 or HPV-16 L1 or L2 DNA twice at 1-week intervals. Splenocytes from vaccinated mice were collected 1 week after last
immunization and pulsed with 5 μg/mL of BPV1 or HPV-16 L1/L2 VLPs. The BPV1 L1/ L2-specific CD4+ T cell immune responses were
characterized using intracellular cytokine staining followed by flow cytometry analysis. a Representative flow cytometry data depicting the
number of BPV1 L1/L2-specific CD4+ T cells. b Bar graph representing the number of BPV1 L1/L2-specific CD4+ T cells/3x105 splenocytes
(mean± SD). c Representative flow cytometry data depicting the number of HPV-16 L1/L2-specific CD4+ T cells. d Bar graph representing the
number of HPV-16 L1/L2-specific CD4+ T cells/3x105 splenocytes (mean± SD). Data shown are representative of two experiments performed. *
indicates p < 0.05
Fig. 4 In vivo tumor treatment experiments in mice vaccinated with CRT/E7 DNA mixed with BPV1 L1 DNA. C57BL/6 mice (five per group) were
first challenged with 1x105/mouse of TC-1 tumor cells subcutaneously. One week after tumor challenge, mice were treated intradermally via gene
gun with 2 μg/mouse of CRT/E7 DNA alone, BPV1 L1 DNA alone or CRT/E7 DNA in combination with BPV1 L1 DNA. Vaccinated mice were
boosted twice at 1-week intervals with the same dose and regimen. Mice were sacrificed on day 30 after the last vaccination. Tumor growth were
monitored twice weekly by caliper measurements and palpations. a Line graph depicting the tumor volume over time of tumor-bearing mice
treated with CRT/E7 DNA and/or BPV1 L1 DNA. b Kaplan-Meier survival analysis of tumor-bearing mice treated with CRT/E7 DNA and/or BPV1 L1
DNA. The data presented are from one representative experiment of the two performed. * indicates p < 0.05
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DNA (data not shown). The insert sequences does not
express into L1 and L2 that activate CD4+ T cell help,
thereby cannot enhance the E7-specific CD8+ T cell re-
sponses of the CRT/E7 vaccine. The result suggests that
CD4+ T cell help generated by co-expression of L1 or
L2 protein promotes E7-specific CD8+ T cell immune
responses to CRT/E7 DNA vaccination.Co-administration of BPV1 L1 DNA with CRT/E7 DNA led
to the generation of L1-specific neutralizing antibodies
In order to determine if co-administration of BPV1 L1
DNA with CRT/E7 DNA will lead to the generation of
BPV1 L1-specific neutralizing antibodies, C57BL/6 mice
(three per group) were immunized on days 1, 15, and 30
intradermally via gene gun with CRT/E7 and/or BPV1
L1 DNA. In vitro neutralization assays were performed
using BPV1 L1 pseudovirus on twofold dilutions of anti-
sera collected from the mice 2 weeks after the final
immunization. Mice vaccinated with CRT/E7 in combin-
ation with BPV1 L1 DNA were found to generate similar
neutralizing antibody responses compared to mice vacci-
nated with BPV1 L1 DNA alone (Fig. 5).Fig. 5 Characterization of BPV1-specific neutralizing antibody re-
sponses generated by mice vaccinated with CRT/E7 and/or BPV1 L1
DNA. C57BL/6 mice (three per group) were immunized on days 1,
15, and 30 intradermally using a gene gun with 2 μg of DNA per
mouse of CRT/E7 and/or BPV1 L1 DNA. In vitro neutralization assays
were performed using BPV1 L1 pseudovirus on twofold dilutions of
antisera collected from the mice 2 weeks after the final
immunization. Endpoint titers achieving 50 % neutralization are
plotted and the means shown as horizontal lines. PI = Pre Immune;
L1 = BPV1 L1 DNA vaccine; E7 = CRT/E7 DNA vaccineCo-administration of BPV1 L1 or L2 DNA with OVA DNA
vaccination generated OVA-specific CD8+ T cell response
through intramuscular administration
Finally, we evaluate whether co-administration with
papillomavirus L1 or L2 DNA can elicit potent antigen-
specific CD8+ T cell responses when applied through
different route of administration. C57BL/6 mice (three per
group) were vaccinated intramuscularly with OVA DNA
with or without BPV1 L1 or L2 DNA twice at one-week
intervals. One week after the last immunization, PBMCs
were collected and the OVA-specific CD8+ T cell immune
responses were characterized through flow cytometry ana-
lysis. As shown in Fig. 6, mice vaccinated intramuscularly
with OVA DNA in combination with BPV1 L1 or L2
DNA generated significantly higher percentage of OVA-
specific CD8+ T cells compared to mice vaccinated intra-
muscularly with OVA DNA alone. This data indicates that
co-administration with papillomavirus L1 or L2 DNA can
lead to enhanced antigen-specific CD8+ T cell immune re-
sponses through the intramuscular route of administration.
Discussion
In the current study, we showed that co-administration
of vectors containing codon-optimized BPV1 or HPV-
16 L1 or L2 in combination with DNA vaccines could
elicit enhanced antigen-specific CD8+ in both CRT/E7
and ovalbumin (OVA) antigenic systems. We also dem-
onstrated that co-administration of BPV1 or HPV-16 L1
or L2 DNA with CRT/E7 DNA led to the generation of
L1/L2-specific CD4+ T cell immune responses. In
addition, the observed enhancement of E7-specific CD8+
T cell immune responses by L1 DNA also confers
improved therapeutic antitumor effects against an E7-
expressing tumor. Moreover, co-administration of BPV1
L1 DNA induced generation of L1-specific neutralizing
antibodies, which may serve to prevent further papilloma-
virus infections. Of note, the enhanced antigen-specific
CD8+ T cell responses are observed in intradermal as well
as intramuscular routes of administration. Indeed, we have
already shown that vaccination with vector expressing L1
is protective against vaginal challenge with papillomavirus
pseudovirions [20]. Taken together, our study suggests the
promise of this approach for future clinical translation,
and it can potentially be applied to other antigenic
systems.
Here we show that CD4+ T cell help plays an import-
ant role in the enhancement of antigen-specific CD8+ T
cell immune responses observed in our vaccination regi-
men as co-administration with the reverse sequence of
BPV1 L1 or L2 did not enhance the antigen-specific
CD8+ T cell responses. Studies have shown that L1 and
L2 are generally much more effective in eliciting CD4+
T cell responses [14–18]. While it is possible that BPV
L1 or L2 could elicit some CD8+ T cell responses, we
Fig. 6 Comparison of OVA-specific CD8+ T cell responses induced by pcDNA3-OVA vaccination with or without co-administration of BPV L1 or L2.
a. Schematic illustration of the experiment. Briefly, 5 ~ 8 weeks old female C57BL/6 mice (3 mice/group) were vaccinated with 10 μg/mouse of
pcDNA3-OVA, with either 10 μg/mouse of pcDNA3, or pcDNA3-BPVL1, or pcDNA3-BPVL2 via intramuscular injection. The mice were boosted with
the same regimen once after one week. 7 days after the last vaccination, PBMCs were collected from peripheral blood, stained with FITC-
conjugated anti-mouse CD8a antibody, PE-conjugated OVA peptide (SIINFEKL) loaded H-2Kb tetramer. The data were acquired with FACSCalibur
and analyzed with CellQuest. b. Representative flow cytometry image of PBMC staining. c. Summary of the flow cytometry data
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DNA is the main contributor to the enhanced antigen-
specific CD8+ T cell response observed. Furthermore, it
has been shown that CD4+ T cells can help generate
memory T cells [21, 22]. Though the current study fo-
cuses on characterizing the antigen-specific CD8+ T cell
therapeutic antitumor effect by our vaccination strategy,
it will be of interest for future studies to further
characterize the complete effect of CD4+ T cell and its
ability to generate memory T cell responses for pro-
longed protection.
Our vaccination strategy was able to generate a potent
therapeutic antitumor effect in tumor-bearing mice. Inter-
estingly, co-administration of BPV1 L1 DNA with CRT/E7
DNA generated L1-specific neutralizing antibodies, which
confers prophylactic value. It has also been shown that vac-
cination with L1 DNA induced L1-specific neutralizing
antibodies in Balb/c mice [20]. Therefore, our vaccination
strategy of co-administration of L1 DNA can generate po-
tent antibody responses in more than one genetic back-
ground. Of note, studies have shown that papillomavirus
L2 is generally not as effective in generating L2-specific
neutralizing antibodies [20, 23], thus co-administration with
L1 DNA should be prioritized in future translation.In the current study we show that co-administration
of BPV1 L1 DNA with CRT/E7 led to potent therapeutic
antitumor effects and prolonged survival due to the en-
hanced antigen-specific CD8+ T cell responses by CD4+
T cell help. Since co-administration with HPV16 L1
DNA with CRT/E7 also significantly enhances antigen-
specific CD8+ T cell responses by CD4+ T cell help, we
believe that potent therapeutic antitumor effects should
also be observed. To further promote clinical translation,
subsequent investigations focusing on directly character-
izing the antitumor effects of co-administrating HPV16
L1 with CRT/E7, and whether reversing the sequence of
HPV16 L1 abolishes the antigen-specific CD8+ T cell re-
sponse enhancement should be conducted. In addition,
since our vaccination regimen achieved complete tumor
suppression, the frequency of vaccination may be modi-
fied and further studied to determine the optimal
vaccination regimen. Importantly, our data show that
the current vaccination strategy can generate enhanced
antigen-specific CD8+ T cell responses by both intrader-
mal and intramuscular vaccination. Since DNA vaccines
are commonly applied intramuscularly in the clinic, fu-
ture translation of the current vaccination technology
may focus on the intramuscular route of administration.
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T helper cells to enhance antigen-specific CD8+ T cell-
mediated immune responses generated by therapeutic
HPV DNA vaccines. We have previously demonstrated
that a DNA vaccine encoding invariant chain (Ii) with
the class II-associated invariant peptide (CLIP) region
replaced with the pan HLA-DR binding epitope
(PADRE) could elicit potent PADRE-specific CD4+ T cell
responses in vaccinated mice [24]. In addition, a co-
administration of this DNA construct (Ii-PADRE) with
DNA encoding HPV-16 E7 generated significantly
greater CD8+ T cell immune responses relative to a co-
administration of DNA encoding HPV-16 E7 with DNA
encoding unmodified Ii [24]. Thus, the current study
represents another promising approach to enhance CD4+
T help for the improvement of DNA vaccine potency, but
with the added benefit of inducing prophylactic immunity
too. It will be of interest in the future to perform a head-
to-head comparison between vectors containing BPV L1/
L2 DNA with Ii-PADRE DNA for their ability to enhance
antigen-specific CD8+ T cell responses by therapeutic
HPV DNA vaccines. Such information will facilitate the
selection of the most effective or desirable DNA construct
for improving DNA vaccine potency.
Another potential mechanism for enhancing the thera-
peutic HPV DNA vaccine potency through the co-
administration with L1/L2 DNA is the potential formation
of VLPs in transfected cells. It has been shown that the ex-
pression of L1 can lead to the formation of VLPs in
eukaryotic cells [25]. Furthermore, previous studies have
demonstrated that papillomavirus VLPs can directly acti-
vate dendritic cells and thereby increase expression of
costimulatory markers and MHC class I and II molecules
[26–28]. Thus, the co-administration of L1 DNA may lead
to the local activation of DCs, resulting in further
enhancement of antigen-specific CD8+ T cell immune re-
sponses generated by DNA vaccination. However, since
the L2 only expression construct had a similar effect to L1
DNA, this suggests that the presence of VLP does not ex-
plain the enhanced CD8 T cell response upon co-
administration with CRT-E7 or OVA constructs.
Strategies to enhance CD4+ T cell help may potentially
be combined with other strategies to further enhance
DNA vaccine potency. We have previously demonstrated
a significant enhancement of DNA vaccine potency by
combining a strategy to prolong dendritic cell life and
intracellular targeting strategies with a strategy to boost
CD4+ T cell help [29]. Since all these strategies function
via different mechanisms, the combination may poten-
tially result in significantly enhanced antigen-specific im-
mune responses and improved antitumor effects. For
clinical translation, it will be desirable to identify the
best combination of the different strategies in order to
achieve the best DNA vaccine potency.Conclusions
In summary, our study demonstrates that the employ-
ment of DNA encoding papillomavirus L1 or L2 can
lead to generation of antigen-specific CD4+ T cells and
neutralizing antibodies, resulting in the improvement of
therapeutic and preventive HPV DNA vaccine potency.
Our strategy may potentially be extended to other anti-
genic systems for the control of infection and/or cancer.
Materials & Methods
Mice
C57BL/6 mice (6–8 weeks old) were purchased from the
National Cancer Institute (Frederick, MD). All animals
were maintained under specific pathogen-free conditions
at the Johns Hopkins Hospital (Baltimore, MD). All pro-
cedures were performed according to the Johns Hopkins
Institutional Care and Use Committee approved proto-
cols and in accordance with recommendations for the
proper care of laboratory animals.
Cells and DNA constructs
TC-1 cells were obtained by co-transformation of pri-
mary C57BL/6 mouse lung epithelial cells with HPV-16
E6 and E7 and an activated ras oncogene as described
previously [30]. They were maintained in RPMI medium
supplemented with 2 mM glutamine, 1 mM sodium
pyruvate, 20 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES), 5x105 M β-mercaptoethanol,
100 IU ml−1 penicillin, 100 μg ml−1 streptomycin, 10 %
fetal bovine serum, and cultured at 37 °C in a humidified
incubator with 5 % CO2. The pcDNA3-OVA and
pcDNA3-CRT/E7 DNA constructs were generated as
described previously [6, 31].
DNA vaccination
DNA-coated gold particles were prepared as described
previously [32]. DNA-coated gold particles were deliv-
ered to the shaved abdominal region of mice using a
helium-driven gene gun (Bio-Rad Laboratories Inc.,
Hercules, CA, USA) with a discharge pressure of 400
p.s.i. C57BL/6 mice were immunized with 2 μg of plas-
mid DNA to each mouse encoding pcDNA3-CRT/E7
mixed with pcDNA3-BPV1-L1 or L2 or HPV-L1 or L2
delivered to the shaved abdomen. The mice received a
homologous boost 1 week later.
C57BL/6 mice were vaccinated with 10 μg of pcDNA3-
OVA DNA with 10 μg of pcDNA3, pcDNA3-BPVL1, or
pcDNA3-BPVL2 intramuscularly in the thigh muscle. The
mice received a homologous boost 1 week later
Intracellular cytokine staining and flow cytometry analysis
Splenocytes were harvested from mice 1 week after the
last vaccination. Prior to intracellular cytokine staining,
5x106 splenocytes from each vaccination group were
Yang et al. Cell & Bioscience  (2015) 5:35 Page 9 of 10incubated for 16 h with 1 μg ml−1 HPV-16 E7 H-2Db
epitope (RAHYNIVTF) or OVA peptide (ISQAVHAA-
HAEINEAGR) [31], or 5 μg/mL BPV1 or HPV-16 L1/L2
VLPs in the presence of GolgiPlug (BD Pharmingen)
(1 μl ml−1). The stimulated splenocytes were then
washed once with FACScan buffer and stained with
phycoerythrin- conjugated monoclonal rat anti-mouse
CD8α or CD4. Cells were subjected to intracellular
cytokine staining using the Cytofix/Cytoperm kit
according to the manufacturer’s instructions (BD Phar-
mingen). Intracellular IFN-γ was stained with fluores-
cein isothiocyanate-conjugated rat anti-mouse IFN-γ to
identify the immune response and cytokine levels.
PBMCs were collected from peripheral blood 1 week
after last intramuscular vaccination and stained with
anti-mouse CD8α and OVA peptide (SIINFEKL) loaded
H-2Kb tetramer. Flow cytometry analysis was per-
formed using FACSCalibur with CELLQuest software
(BD Biosciences, Mountain View, CA, USA).In vivo tumor treatment experiments
C57BL/6 mice (five per group) were inoculated subcuta-
neously with 1xl05 TC-1 tumor cells per mouse on the
left flank. After 1 week, when tumor progression is usu-
ally observed, mice were vaccinated with DNA con-
structs pcDNA3-BPV1 L1 or L2 or pcDNA3-HPV L1 or
L2 in conjunction with pCDNA3-CRT/E7 or pcDNA3-
OVA or the control empty vector. A homologous boost
was administered 1 week after the first immunization.
Mice were monitored for tumor growth by measuring
diameters with calipers twice a week.Neutralization assays
The BPV1 L1, L2 and HPV L1, L2 pseudovirions with
encapsulated secreted alkaline phosphatase (SEAP)
were generated by co-transfection of 293TT cells with
plasmids encoding BPV1 L1, L2 or HPV L1 and L2
and a SEAP reporter plasmid as described previously
[33]. Cells collected after transfection were treated
overnight with Brij 58 (0.5 %), Benzonase (0.5 %) and
purified by centrifugation on an Optiprep step gradi-
ent (27, 33, and 39 %) at 40,000 rpm for 4.5 h. Pseudo-
virus neutralization assays were carried out as
outlined previously [34]. Briefly, the pseudovirus and
the pooled mouse immune sera were incubated for 1 h
and the mixture was used to infect 293TT cells. 68–72
h post-infection, the supernatants were collected and
SEAP activity in the supernatants was measured by
colorimetric assay. Serum neutralization titers were
defined as the highest dilution that caused at least a
50 % reduction in SEAP activity, compared to control
pre-immune serum samples.Statistical analysis
All data expressed as means ± s.d. are representative of
at least two different experiments. Data for intracellular
cytokine staining with flow cytometry analysis and
tumor treatment experiments were evaluated by analysis
of variance. Comparisons between individual data points
were made using Student’s t-test. All p values < 0.05 were
considered significant.
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